Associations with selected NHL subtypes for baseline serum concentrations of BCA-1, sTNFR2, sVEGFR2, IL-16, TRAIL, and amylin
| . | Controls . | CLL/SLL . | DLBCL . | FL . | Test of OR Homogeneity . | |||
|---|---|---|---|---|---|---|---|---|
| Analyte concentration (pg/mL)* . | N . | N . | OR† (95% CI) . | N . | OR† (95% CI) . | N . | OR† (95% CI) . | P . |
| BCA-1 | ||||||||
| <15.57 | 151 | 45 | 1.0 | 16 | 1.0 | 12 | 1.0 | |
| ≥15.57 | 150 | 61 | 1.4 (0.9-2.2) | 55 | 3.3 (1.8-6.2) | 29 | 2.8 (1.3-5.7) | .03 |
| BCA-1 | ||||||||
| <4896.03 | 151 | 31 | 1.0 | 18 | 1.0 | 14 | 1.0 | |
| ≥4896.03 | 150 | 75 | 2.6 (1.6-4.3) | 53 | 2.8 (1.5-5.2) | 27 | 2.2 (1.1-4.5) | .86 |
| TNF-α | ||||||||
| <5.04 | 151 | 46 | 1.0 | 23 | 1.0 | 6 | 1.0 | |
| ≥5.04 | 150 | 60 | 1.3 (0.8-2.1) | 48 | 2.1 (1.2-3.7) | 35 | 6.0 (2.4-15.0) | .008 |
| sVEGFR2 | ||||||||
| <11 279.23 | 151 | 38 | 1.0 | 25 | 1.0 | 17 | 1.0 | |
| ≥11 279.23 | 150 | 68 | 1.8 (1.1-2.9) | 46 | 2.1 (1.2-3.7) | 24 | 1.4 (0.7-2.8) | .67 |
| IL-16 | ||||||||
| <24.90 | 152 | 49 | 1.0 | 25 | 1.0 | 15 | 1.0 | |
| ≥24.90 | 149 | 57 | 1.2 (0.8-1.9) | 46 | 1.9 (1.1-3.3) | 26 | 1.9 (0.9-3.8) | .26 |
| TRAIL | ||||||||
| <31.41 | 151 | 33 | 1.0 | 28 | 1.0 | 15 | 1.0 | |
| ≥31.41 | 150 | 73 | 2.5 (1.5-4.1) | 43 | 1.5 (0.9-2.6) | 26 | 1.8 (0.9-3.7) | .29 |
| Amylin | ||||||||
| <LLOD | 171 | 48 | 1.0 | 34 | 1.0 | 19 | 1.0 | |
| Detectable | 130 | 58 | 1.7 (1.1-2.8) | 37 | 1.6 (0.9-2.8) | 22 | 1.5 (0.7-3.0) | .92 |
| . | Controls . | CLL/SLL . | DLBCL . | FL . | Test of OR Homogeneity . | |||
|---|---|---|---|---|---|---|---|---|
| Analyte concentration (pg/mL)* . | N . | N . | OR† (95% CI) . | N . | OR† (95% CI) . | N . | OR† (95% CI) . | P . |
| BCA-1 | ||||||||
| <15.57 | 151 | 45 | 1.0 | 16 | 1.0 | 12 | 1.0 | |
| ≥15.57 | 150 | 61 | 1.4 (0.9-2.2) | 55 | 3.3 (1.8-6.2) | 29 | 2.8 (1.3-5.7) | .03 |
| BCA-1 | ||||||||
| <4896.03 | 151 | 31 | 1.0 | 18 | 1.0 | 14 | 1.0 | |
| ≥4896.03 | 150 | 75 | 2.6 (1.6-4.3) | 53 | 2.8 (1.5-5.2) | 27 | 2.2 (1.1-4.5) | .86 |
| TNF-α | ||||||||
| <5.04 | 151 | 46 | 1.0 | 23 | 1.0 | 6 | 1.0 | |
| ≥5.04 | 150 | 60 | 1.3 (0.8-2.1) | 48 | 2.1 (1.2-3.7) | 35 | 6.0 (2.4-15.0) | .008 |
| sVEGFR2 | ||||||||
| <11 279.23 | 151 | 38 | 1.0 | 25 | 1.0 | 17 | 1.0 | |
| ≥11 279.23 | 150 | 68 | 1.8 (1.1-2.9) | 46 | 2.1 (1.2-3.7) | 24 | 1.4 (0.7-2.8) | .67 |
| IL-16 | ||||||||
| <24.90 | 152 | 49 | 1.0 | 25 | 1.0 | 15 | 1.0 | |
| ≥24.90 | 149 | 57 | 1.2 (0.8-1.9) | 46 | 1.9 (1.1-3.3) | 26 | 1.9 (0.9-3.8) | .26 |
| TRAIL | ||||||||
| <31.41 | 151 | 33 | 1.0 | 28 | 1.0 | 15 | 1.0 | |
| ≥31.41 | 150 | 73 | 2.5 (1.5-4.1) | 43 | 1.5 (0.9-2.6) | 26 | 1.8 (0.9-3.7) | .29 |
| Amylin | ||||||||
| <LLOD | 171 | 48 | 1.0 | 34 | 1.0 | 19 | 1.0 | |
| Detectable | 130 | 58 | 1.7 (1.1-2.8) | 37 | 1.6 (0.9-2.8) | 22 | 1.5 (0.7-3.0) | .92 |
CI, confidence interval; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; OR, odds ratio.
Analytes with 50% or more of samples above the LLOD were categorized using the median concentration among controls as cutpoint. Analytes with less than 50% of samples above the LLOD categorized as <LLOD vs detectable.
Odds ratios computed using polytomous regression with adjustment for age group at baseline, sex, race, study center, and blood collection date.